4,323 results on '"chronic kidney disease-mineral and bone disorder"'
Search Results
2. The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients (ProliaKTx)
- Author
-
Thomas Nickolas, MD MS, Associate Professor of Medicine
- Published
- 2024
3. Precision Medicine Approaches to Renal Osteodystrophy (PMaROD)
- Author
-
Indiana University School of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Thomas Nickolas, MD MS, Professor of Medicine
- Published
- 2024
4. DePTH: De-emphasize PTH
- Author
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Simon Hsu, MD, MS, Assistant Professor
- Published
- 2024
5. Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
- Author
-
Indiana University
- Published
- 2024
6. Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
- Author
-
Odense University Hospital, Steno Diabetes Center Copenhagen, Rigshospitalet, Denmark, Aalborg University Hospital, and Ditte Hansen, MD, PhD
- Published
- 2024
7. Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
- Author
-
Ekaterina Parshina, Principal investigator
- Published
- 2024
8. Chinese CKD-MBD Prevalence Survey (CRISS-MBD)
- Author
-
Limeng Chen, Deputy Director, Department of Nephrology
- Published
- 2024
9. Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients (NGAL)
- Author
-
Xiaoyan Jia, Clinical Professor
- Published
- 2024
10. Fucoidan Ameliorates Renal Injury-Related Calcium-Phosphorus Metabolic Disorder and Bone Abnormality in the CKD-MBD Model Rats by Targeting FGF23-Klotho Signaling Axis.
- Author
-
Bu-Hui Liu, Fee-Lan Chong, Can-Can Yuan, Ying-Lu Liu, Hai-Ming Yang, Wen-Wen Wang, Qi-Jun Fang, Wei Wu, Mei-Zi Wang, Yue Tu, Zi-Yue Wan, Yi-Gang Wan, and Guo-Wen Wu
- Subjects
RENAL osteodystrophy ,METABOLIC bone disorders ,LABORATORY rats ,KIDNEY diseases ,TREATMENT effectiveness - Abstract
Background: Recently, chronic kidney disease (CKD)-mineral and bone disorder (MBD) has become one of common complications occurring in CKD patients. Therefore, development of a new treatment for CKD-MBD is very important in the clinic. In China, Fucoidan (FPS), a natural compound of Laminaria japonica has been frequently used to improve renal dysfunction in CKD. However, it remains elusive whether FPS can ameliorate CKD-MBD. FGF23-Klotho signaling axis is reported to be useful for regulating mineral and bone metabolic disorder in CKD-MBD. This study thereby aimed to clarify therapeutic effects of FPS in the CKD-MBD model rats and its underlying mechanisms in vivo and in vitro, compared to Calcitriol (CTR). Methods: All male rats were divided into four groups: Sham, CKD-MBD, FPS and CTR. The CKD-MBD rat models were induced by adenine administration and uninephrectomy, and received either FPS or CTR or vehicle after induction of renal injury for 21 days. The changes in parameters related to renal dysfunction and renal tubulointerstitial damage, calcium-phosphorus metabolic disorder and bone lesion were analyzed, respectively. Furthermore, at sacrifice, the kidneys and bone were isolated for histomorphometry, immunohistochemistry and Western blot. In vitro, the murine NRK-52E cells were used to investigate regulative actions of FPS or CTR on FGF23-Klotho signaling axis, ERK1/2-SGK1-NHERF-1-NaPi-2a pathway and Klotho deficiency. Results: Using the modified CKD-MBD rat model and the cultured NRK-52E cells, we indicated that FPS and CTR alleviated renal dysfunction and renal tubulointerstitial damage, improved calcium-phosphorus metabolic disorder and bone lesion, and regulated FGF23-Klotho signaling axis and ERK1/2-SGK1-NHERF-1-NaPi-2a pathway in the kidney. In addition, using the shRNA-Klotho plasmid-transfected cells, we also detected, FPS accurately activated ERK1/2-SGK1-NHERF-1-NaPi-2a pathway through Klotho loss reversal. Conclusion: In this study, we emphatically demonstrated that FPS, a natural anti-renal dysfunction drug, similar to CTR, improves renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD-MBD model rats. More importantly, we firstly found that beneficial effects in vivo and in vitro of FPS on phosphorus reabsorption are closely associated with regulation of FGF23-Klotho signaling axis and ERK1/2-SGK1-NHERF-1-NaPi-2a pathway in the kidney. This study provided pharmacological evidences that FPS directly contributes to the treatment of CKD-MBD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Improving Phosphate Control in Children With CKD (IMPACT)
- Author
-
Rukshana Shroff1, Professor
- Published
- 2023
12. Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease
- Author
-
Yosuke Nakagawa and Hirotaka Komaba
- Subjects
chronic kidney disease-mineral and bone disorder ,fibroblast growth factor-23 ,glycerol-3-phosphate ,parathyroid hormone ,hyperparathyroidism, secondary ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) each play a central role in the pathogenesis of chronic kidney disease (CKD)-mineral and bone disorder. Levels of both hormones increase progressively in advanced CKD and can lead to damage in multiple organs. Secondary hyperparathyroidism (SHPT), characterized by parathyroid hyperplasia with increased PTH secretion, is associated with fractures and mortality. Emerging evidence suggests that these associations may be partially explained by PTH-induced browning of adipose tissue and increased energy expenditure. Observational studies suggest a survival benefit of PTHlowering therapy, and a recent study comparing parathyroidectomy and calcimimetics further suggests the importance of intensive PTH control. The mechanisms underlying the regulation of FGF23 secretion by osteocytes in response to phosphate load have been unclear, but recent experimental studies have identified glycerol-3-phosphate, a byproduct of glycolysis released by the kidney, as a key regulator of FGF23 production. Elevated FGF23 levels have been shown to be associated with mortality, and experimental data suggest off-target adverse effects of FGF23. However, the causal role of FGF23 in adverse outcomes in CKD patients remains to be established. Further studies are needed to determine whether intensive SHPT control improves clinical outcomes and whether treatment targeting FGF23 can improve patient outcomes.
- Published
- 2024
- Full Text
- View/download PDF
13. Effect of mobile APP in the management and application of mineral and bone disorder in dialysis patients of chronic kidney disease
- Author
-
Gulimire Muhetaer, Yue Qu, Xiao-wen Ha, Ling Zhang, Xiao-yu Wang, Yong-wu Yu, and Hong Jiang
- Subjects
chronic kidney disease ,chronic kidney disease-mineral and bone disorder ,mobile application program ,Internal medicine ,RC31-1245 - Abstract
Objective To explore the adjustment and impact of chronic kidney disease-mineral and bone disorder (CKD-MBD) parameters in maintenance dialysis patients utilizing the Doctor-Patient Care App (Renal Care App). Methods From August 2021 to March 2022, 102 maintenance dialysis (HD) and peritoneal dialysis (PD) patients were randomized into two groups of App management or control (n=51 each). Control group received standard treatment for CKD-MBD while App management group was treated with CKD-MBD management model facilitated by Renal Care App. Follow-up assessments occurred every 3 months over a 12-month period. Changes in serum calcium (Ca), serum phosphorus (P) and serum parathyroid hormone (iPTH) levels were recorded along with patient satisfaction and revisit rates. Results From August 2021 to March 2022, 102 maintenance dialysis (HD) and peritoneal dialysis (PD) patients were randomized into two groups of App management or control (n=51 each). Control group received standard treatment for CKD-MBD while App management group was treated with CKD-MBD management model facilitated by Renal Care App. Follow-up assessments occurred every 3 months over a 12-month period. Changes in serum calcium (Ca), serum phosphorus (P) and serum parathyroid hormone (iPTH) levels were recorded along with patient satisfaction and revisit rates. Conclusions Interventions utilizing the App management model prove advantageous in elevating the rate of CKD-MBD-related parameters attaining the standards among regular dialysis patients. This approach not only improves patient compliance and satisfaction but also demonstrates clinical significance for broader applications.
- Published
- 2024
- Full Text
- View/download PDF
14. Advances in Metabolic Reprogramming of Osteoblasts with the Development of Early Renal Bone Disease
- Author
-
WANG Zuoyu, ZHOU Yang, XIONG Mingxia, ZHAO Shasha, YANG Junwei
- Subjects
chronic kidney disease-mineral and bone disorder ,renal bone disease ,cellular reprogramming ,fibroblast growth factor-23 ,Medicine - Abstract
Chronic kidney disease-mineral and bone disorder (CKD-MBD) has a direct impact on patients' quality of life, hospitalization rates and fracture risk. In recent years, osteoblasts and osteoclasts have become central to the pathophysiology of CKD-MBD. Osteoblasts interact with other organs by synthesizing fibroblast growth factor-23 (FGF-23) and sclerostin (SOST), making the skeleton an endocrine organ. Therefore, dysregulation of osteoblast differentiation is an important early event in the pathogenesis of CKD. In this paper, we systematically discuss the metabolic pathways of osteoblasts and the mechanisms related to the altered metabolic reprogramming of osteoblasts in the early CKD-MBD pathology. This paper shows that abnormalities in signaling pathways and metabolites such as Wnt/β-catenin, FGF-23, uremic toxins, metabolic acidosis, can alter the metabolic activity of osteoblasts, causing impaired maturation of the osteogenic spectrum, which in turn affects bone remodeling, which will provide a new way of thinking for explaining the pathological changes in renal bone disease and developing clinical treatment options.
- Published
- 2024
- Full Text
- View/download PDF
15. Bilateral Femoral Neck Fractures in a 50-Year-Old Patient with Chronic Kidney Disease.
- Author
-
Albishi, Waleed, Alshehri, Rahmah, Almuhanna, Abdulaziz, Baaj, Jumana M. Z., Alaqeel, Motaz, and Algarni, Nizar
- Subjects
- *
RENAL osteodystrophy , *FEMORAL neck fractures , *SURGICAL complications , *MEDICAL care , *FEMORAL fractures , *HIP fractures - Abstract
Objective: Unusual clinical course Background: Renal osteodystrophy is a serious complication of advanced chronic kidney disease (CKD). It predisposes the patient to fragility fracture and an increased risk of mortality. Case Report: We present the case of a 50-year-old male patient with stage 4 CKD and consequent renal osteodystrophy, who presented with a history of a recent provoked seizure, a severe electrolyte imbalance, and excruciating pain in the hip region. He had no history of a fall or trauma. A radiographic evaluation confirmed the rare finding of a bilateral femoral neck fracture. Upon stabilizing the patient, he was surgically managed with a bilateral hemiarthroplasty. A postoperative radiograph revealed a well-fixed prosthesis with no post-surgical complications. The patient had a full recovery. At the last follow-up visit, the patient was fully functional and had resumed normal activities. Conclusions: This is a rare report with unusual mechanism of injury, involving a case of bilateral femoral neck fragility fractures, secondary to renal osteodystrophy in a stage 4 CKD patient. It draws the attention of medical care providers to the high risk of femoral fragility fractures that are secondary to renal osteodystrophy. Hemiarthroplasty is a safe and highly efficacious surgical option for managing such cases. This case also reiterates the dire need for greater public awareness and knowledge of CKD. Early diagnosis and treatment can substantially mitigate the associated morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Seeing the Whole Picture: Evaluating the Contribution of Whole Grains to Phosphorus Exposure in People With Kidney Failure Undergoing Dialysis Treatment.
- Author
-
Winkelman, Dillon, Gallant, Kathleen Hill, Moe, Sharon, and St‐Jules, David E.
- Subjects
- *
KIDNEY failure , *RENAL osteodystrophy , *DIALYSIS (Chemistry) , *PHOSPHORUS - Abstract
Excessive dietary phosphorus is a concern among patients with kidney failure undergoing dialysis treatment because it may contribute to hyperparathyroidism and hyperphosphatemia. A long‐standing but untested component of the low‐phosphorus diet is the promotion of refined grains over whole grains. This paper reviews the scientific premise for restricting whole grains in the dialysis population and estimates phosphorus exposure from grain products based on three grain intake patterns modeled from reported intakes in the general US population, adjusting for the presence of phosphorus additives and phosphorus bioavailability: (1) standard grain intake, (2) 100% refined grain intake, and (3) mixed (50/50 whole and refined grain) intake. Although estimated phosphorus exposure from grains was higher with the mixed grain pattern (231 mg/day) compared to the 100% refined grain pattern (127 mg/day), the amount of additional phosphorus from grains was relatively low. Given the lack of strong evidence for restricting whole grains in people with CKD, as well as the potential health benefits of whole grains, clinical trials are warranted to address the efficacy and health impact of this practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Transcription factor HNF4α2 promotes osteogenesis and prevents bone abnormalities in mice with renal osteodystrophy.
- Author
-
Martinez-Calle, Marta, Courbon, Guillaume, Hunt-Tobey, Bridget, Francis, Connor, Spindler, Jadeah, Wang, Xueyan, Dos Reis, Luciene M, Martins, Carolina Sw, Salusky, Isidro B, Malluche, Hartmut, Nickolas, Thomas L, Moyses, Rosa Ma, Martin, Aline, and David, Valentin
- Subjects
Animals ,Mice ,Transcription Factors ,Gene Expression Regulation ,Osteogenesis ,Renal Insufficiency ,Chronic ,Hepatocyte Nuclear Factor 4 ,Chronic Kidney Disease-Mineral and Bone Disorder ,Bone Biology ,Bone disease ,Chronic kidney disease ,Metabolism ,Genetics ,Rare Diseases ,Kidney Disease ,Prevention ,Biotechnology ,Musculoskeletal ,Renal and urogenital ,Medical and Health Sciences ,Immunology - Abstract
Renal osteodystrophy (ROD) is a disorder of bone metabolism that affects virtually all patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes including fractures, cardiovascular events, and death. In this study, we showed that hepatocyte nuclear factor 4α (HNF4α), a transcription factor mostly expressed in the liver, is also expressed in bone, and that osseous HNF4α expression was dramatically reduced in patients and mice with ROD. Osteoblast-specific deletion of Hnf4α resulted in impaired osteogenesis in cells and mice. Using multi-omics analyses of bones and cells lacking or overexpressing Hnf4α1 and Hnf4α2, we showed that HNF4α2 is the main osseous Hnf4α isoform that regulates osteogenesis, cell metabolism, and cell death. As a result, osteoblast-specific overexpression of Hnf4α2 prevented bone loss in mice with CKD. Our results showed that HNF4α2 is a transcriptional regulator of osteogenesis, implicated in the development of ROD.
- Published
- 2023
18. Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function
- Author
-
University of Copenhagen, Universiteit Antwerpen, and Ditte Hansen, Associate professor
- Published
- 2023
19. The Effect of Etelcalcetide on CKD-MBD (Parsabiv-MBD)
- Author
-
Thomas Nickolas, MD MS, Associate Professor of Medicine
- Published
- 2023
20. Correlation between soluble klotho and chronic kidney disease–mineral and bone disorder in chronic kidney disease: a meta-analysis
- Author
-
Zhongyu Fan, Xuejiao Wei, Xiaoyu Zhu, Kun Yang, Ling Tian, Yujun Du, and Liming Yang
- Subjects
Soluble Klotho ,Chronic kidney disease–mineral and bone disorder ,Chronic kidney disease ,Mineral metabolism ,Vascular calcification ,Medicine ,Science - Abstract
Abstract We conducted a systematic search across medical databases, including PubMed, Web of Science, EMBASE, and Cochrane Library, up to March 2023. A total of 1944 subjects or individuals from 17 studies were included in our final analysis. The correlation coefficient (r) between sKlotho and calcium was [0.14, (0.02, 0.26)], and a moderate heterogeneity was observed (I2 = 66%, P
- Published
- 2024
- Full Text
- View/download PDF
21. Correlation between soluble klotho and chronic kidney disease–mineral and bone disorder in chronic kidney disease: a meta-analysis.
- Author
-
Fan, Zhongyu, Wei, Xuejiao, Zhu, Xiaoyu, Yang, Kun, Tian, Ling, Du, Yujun, and Yang, Liming
- Subjects
- *
RENAL osteodystrophy , *CHRONIC kidney failure , *ARTERIAL calcification - Abstract
We conducted a systematic search across medical databases, including PubMed, Web of Science, EMBASE, and Cochrane Library, up to March 2023. A total of 1944 subjects or individuals from 17 studies were included in our final analysis. The correlation coefficient (r) between sKlotho and calcium was [0.14, (0.02, 0.26)], and a moderate heterogeneity was observed (I2 = 66%, P < 0.05). The correlation coefficient (r) between Klotho and serum phosphate was [− 0.21, (− 0.37, − 0.04)], with apparent heterogeneity (I2 = 84%, P < 0.05). The correlation coefficient (r) between sKlotho and parathyroid hormone and vascular calcification was [− 0.23,(− 0.29, − 0.17); − 0.15, (− 0.23, − 0.08)], with no significant heterogeneity among the studies. (I2 = 40%, P < 0.05; I2 = 30%, P < 0.05). A significant correlation exists between low sKlotho levels and an increased risk of CKD–MBD in patients with CKD. According to the findings, sKlotho may play a role in alleviating CKD–MBD by lowering phosphorus and parathyroid hormone levels, regulating calcium levels, and suppressing vascular calcification. As analysis showed that sKlotho has an important impact on the pathogenesis and progression of CKD–MBD in CKD patients. Nonetheless, further comprehensive and high-quality studies are needed to validate our conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Recommended calcium intake in adults and children with chronic kidney disease—a European consensus statement.
- Author
-
Evenepoel, Pieter, Jørgensen, Hanne Skou, Bover, Jordi, Davenport, Andrew, Bacchetta, Justine, Haarhaus, Mathias, Hansen, Ditte, Gracia-Iguacel, Carolina, Ketteler, Markus, McAlister, Louise, White, Emily, Mazzaferro, Sandro, Vervloet, Marc, and Shroff, Rukshana
- Subjects
- *
BONE fractures , *RENAL osteodystrophy , *PEDIATRIC nephrology , *CHRONIC kidney failure , *HYPERPHOSPHATEMIA , *BONE health , *CALCIUM - Abstract
Mineral and bone disorders (MBD) are common in patients with chronic kidney disease (CKD), contributing to significant morbidity and mortality. For several decades, the first-line approach to controlling hyperparathyroidism in CKD was by exogenous calcium loading. Since the turn of the millennium, however, a growing awareness of vascular calcification risk has led to a paradigm shift in management and a move away from calcium-based phosphate binders. As a consequence, contemporary CKD patients may be at risk of a negative calcium balance, which, in turn, may compromise bone health, contributing to renal bone disease and increased fracture risk. A calcium intake below a certain threshold may be as problematic as a high intake, worsening the MBD syndrome of CKD, but is not addressed in current clinical practice guidelines. The CKD-MBD and European Renal Nutrition working groups of the European Renal Association (ERA), together with the CKD-MBD and Dialysis working groups of the European Society for Pediatric Nephrology (ESPN), developed key evidence points and clinical practice points on calcium management in children and adults with CKD across stages of disease. These were reviewed by a Delphi panel consisting of ERA and ESPN working groups members. The main clinical practice points include a suggested total calcium intake from diet and medications of 800–1000 mg/day and not exceeding 1500 mg/day to maintain a neutral calcium balance in adults with CKD. In children with CKD, total calcium intake should be kept within the age-appropriate normal range. These statements provide information and may assist in decision-making, but in the absence of high-level evidence must be carefully considered and adapted to individual patient needs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients.
- Author
-
Tarasewicz, Agnieszka, Komorniczak, Michał, Zakrzewska, Agnieszka, Biedunkiewicz, Bogdan, Małgorzewicz, Sylwia, Jankowska, Magdalena, Jasiulewicz, Katarzyna, Płonka, Natalia, Dąbrowska, Małgorzata, Dębska-Ślizień, Alicja, and Tylicki, Leszek
- Subjects
CHOLECALCIFEROL ,HEMODIALYSIS patients ,RENAL osteodystrophy ,VITAMIN D deficiency - Abstract
Vitamin D deficiency and insufficiency are highly prevalent in CKD, affecting over 80% of hemodialysis (HD) patients and requiring therapeutic intervention. Nephrological societies suggest the administration of cholecalciferol according to the guidelines for the general population. The aim of the observational study was to evaluate the efficacy and safety of the therapy with a high dose of cholecalciferol in HD patients with 25(OH)D deficiency and insufficiency to reach the target serum 25(OH)D level > 30 ng/mL. A total of 22 patients (16 M), with an average age of 72.5 ± 13.03 years and 25(OH)D concentration of 13.05 (9.00–17.90) ng/mL, were administered cholecalciferol at a therapeutic dose of 70,000 IU/week (20,000 IU + 20,000 IU + 30,000 IU, immediately after each dialysis session). All patients achieved the target value > 30 ng/mL, with a mean time of 2.86 ± 1.87 weeks. In the first week, the target level of 25(OH)D (100%) was reached by 2 patients (9.09%), in the second week by 15 patients (68.18%), in the fourth week by 18 patients (81.18%), and in the ninth week by all 22 patients (100%). A significant increase in 1,25(OH)
2 D levels was observed during the study. However, only 2 patients (9.09%) achieved a concentration of 1,25(OH)2 D above 25 ng/mL—the lower limit of the reference range. The intact PTH concentrations remained unchanged during the observation period. No episodes of hypercalcemia were detected, and one new episode of hyperphosphatemia was observed. In conclusion, our study showed that the administration of a high-therapeutic dose of cholecalciferol allowed for a quick, effective, and safe leveling of 25(OH)D concentration in HD patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
24. Growth in children with chronic kidney disease and associated risk factors for short stature
- Author
-
Virgínia Barbosa de Melo, Danielle Barbosa da Silva, Matheus Dantas Soeiro, Lucas Cavalcante Tenório de Albuquerque, Henderson Edward Firmino Cavalcanti, Marcela Correa Araújo Pandolfi, Rosilene Mota Elias, Rosa Maria Affonso Moysés, and Emília Maria Dantas Soeiro
- Subjects
Renal Insufficiency, Chronic ,Failure to Thrive ,Chronic Kidney Disease-Mineral and Bone Disorder ,Growth ,Child Nutrition ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Introduction: Growth failure in chronic kidney disease is related to high morbidity and mortality. Growth retardation in this disease is multifactorial. Knowing the modifiable factors and establishing strategies to improve care for affected children is paramount. Objectives: To describe growth patterns in children with chronic kidney disease and the risk factors associated with short stature. Methods: We retrospectively analyzed anthropometric and epidemiological data, birth weight, prematurity, and bicarbonate, hemoglobin, calcium, phosphate, alkaline phosphatase, and parathormone levels of children with stages 3–5 CKD not on dialysis, followed for at least one year. Results: We included 43 children, the majority of which were boys (65%). The mean height/length /age z-score of the children at the beginning and follow-up was –1.89 ± 1.84 and –2.4 ± 1.67, respectively (p = 0.011). Fifty-one percent of the children had short stature, and these children were younger than those with adequate stature (p = 0.027). PTH levels at the beginning of the follow-up correlated with height/length/age z-score. A sub-analysis with children under five (n = 17) showed that 10 (58.8%) of them failed to thrive and had a lower weight/age z-score (0.031) and lower BMI/age z-score (p = 0.047). Conclusion: Children, particularly younger ones, with chronic kidney disease who were not on dialysis had a high prevalence of short stature. PTH levels were correlated with height z-score, and growth failure was associated with worse nutritional status. Therefore, it is essential to monitor the growth of these children, control hyperparathyroidism, and provide nutritional support.
- Published
- 2024
- Full Text
- View/download PDF
25. Corrigendum: Fucoidan ameliorates renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD–MBD model rats by targeting FGF23-Klotho signaling axis
- Author
-
Bu-Hui Liu, Fee-Lan Chong, Can-Can Yuan, Ying-Lu Liu, Hai-Ming Yang, Wen-Wen Wang, Qi-Jun Fang, Wei Wu, Mei-Zi Wang, Yue Tu, Zi-Yue Wan, Yi-Gang Wan, and Guo-Wen Wu
- Subjects
fucoidan ,chronic kidney disease-mineral and bone disorder ,FGF23-klotho signaling axis ,phosphorus reabsorption ,ERK1/2-SGK1-NHERF-1-NaPi-2a pathway ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2024
- Full Text
- View/download PDF
26. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b–4 chronic kidney disease and osteoporosis
- Author
-
Jin Taek Kim, You Mi Kim, Kyong Yeun Jung, Hoonsung Choi, So Young Lee, and Hyo-Jeong Kim
- Subjects
denosumab ,chronic kidney disease-mineral and bone disorder ,osteoporosis ,vascular calcification ,Medicine - Abstract
Background/Aims We evaluated the efficacy and safety of denosumab treatment in severe chronic kidney disease (CKD) patients with osteoporosis. We also investigated whether the treatment affects the coronary artery calcifications. Methods Twenty-seven postmenopausal women with Stage 3b–4 CKD and osteoporosis were enrolled. Twenty patients received denosumab plus calcium carbonate and vitamin D, and seven controls received calcium carbonate and vitamin D for 1 year. Dual-energy X-ray absorptiometry and coronary artery calcium (CAC) scoring computed tomography were performed before and after treatment. Hypocalcemic symptoms and serum calcium levels were evaluated. Results After 1 year of treatment, the percent changes of femur neck (3.6 ± 3.2% vs. −0.7 ± 4.4%, p = 0.033) and total hip (3.4 ± 3.8% vs. −1.9 ± 2.1%, p = 0.001) bone mineral density (BMD) were significantly increased in the denosumab treated group compared to the control group. However, the percent change of lumbar spine BMD did not differ between two groups (5.6 ± 5.9% vs. 2.7 ± 3.9%, p = 0.273). The percent change of bone alkaline phosphatase was significantly different in the denosumab-treated group and control group (−31.1 ± 30.0% vs. 0.5 ± 32.0%, p = 0.027). CAC scores did not differ between groups. No hypocalcemic events occurred in both groups. Conclusions If carefully monitored and supplemented with calcium and vitamin D, denosumab treatment for 1 year provides significant benefits in patients with Stage 3b–4 CKD and osteoporosis. However, denosumab treatment did not affect coronary artery calcifications in these patients.
- Published
- 2024
- Full Text
- View/download PDF
27. Association between serum magnesium levels and cognitive function in patients undergoing hemodialysis
- Author
-
Kato, Kazuhiko, Nakashima, Akio, Shinagawa, Shunichiro, Kobayashi, Arisa, Ohkido, Ichiro, Urashima, Mitsuyoshi, and Yokoo, Takashi
- Published
- 2024
- Full Text
- View/download PDF
28. Renal Osteodystrophy: An Individual Management Approach
- Author
-
Wright State University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Hartmut Malluche, MD, Principal Investigator
- Published
- 2022
29. Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). (TeriCa)
- Author
-
Novokshonov Konstantin, MD, PHD
- Published
- 2022
30. Understanding the Korean Dialysis Cohort for Mineral, Vascular Calcification, and Fracture (ORCHESTRA) Study: Design, Method, and Baseline Characteristics.
- Author
-
Ahn, Shin Young, Ko, Gang Jee, Hwang, Hyeon Seok, Jeong, Kyung Hwan, Jin, Kyubok, Kim, Yang Gyun, Moon, Ju-Young, Lee, Sang Ho, Lee, So-Young, Yang, Dong-Ho, Jung, Ji Yong, Oh, Kook-Hwan, Lee, Young-Ki, Kim, Gheun-Ho, Kim, Soo Wan, Kim, Yeong Hoon, Lee, Dong-Young, Hong, Yu Ah, Park, Hyeong Cheon, and Yoon, Sun Ae
- Subjects
- *
RENAL osteodystrophy , *ARTERIAL calcification , *VETERANS' hospitals , *MAJOR adverse cardiovascular events , *VETERANS' health - Abstract
Introduction: End-stage renal disease (ESRD) is a growing disease worldwide, including Korea. This is an important condition that affects patient outcome. To provide optimal management for mineral disturbance, vascular calcification, and bone disease in ESRD patients, the Korean dialysis cohort for mineral, vascular calcification, and fracture (ORCHESTRA) study was conducted by enrolling Korean dialysis patients. Methods: Sixteen university-affiliated hospitals and one Veterans' Health Service Medical Center participated in this study. This prospective cohort study enrolled approximately 900 consecutive patients on dialysis between May 2019 and January 2021. Enrolled subjects were evaluated at baseline for demographic information, laboratory tests, radiologic imaging, and bone mineral densitometry (BMD) scans. After enrollment, regular assessments of the patients were performed, and their biospecimens were collected according to the study protocol. The primary outcomes were the occurrence of major adverse cardiovascular events, invasive treatment for peripheral artery disease, and osteoporotic fractures. The secondary outcomes were hospitalization for cerebrovascular disease or progression of abdominal aortic calcification. Participants will be assessed for up to 3 years to determine whether primary or secondary outcomes occur. Results: Between May 2019 and January 2021, all participating centers recruited 900 consecutive dialysis patients, including 786 undergoing hemodialysis (HD) and 114 undergoing peritoneal dialysis (PD). The mean age of the subjects was 60.4 ± 12.3 years. Males accounted for 57.7% of the total population. The mean dialysis vintage was 6.1 ± 6.0 years. The HD group was significantly older, had a longer dialysis vintage, and more comorbidities. Overall, the severity of vascular calcification was higher and the level of BMD was lower in the HD group than in the PD group. Conclusion: This nationwide, multicenter, prospective cohort study focused on chronic kidney disease-mineral and bone disorder and aimed to provide clinical evidence to establish optimal treatment guidelines for Asian dialysis patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Relationships between blood bone metabolic biomarkers and anemia in patients with chronic kidney disease.
- Author
-
Li, Fan, Ye, Xiaoxue, Yang, Guang, Huang, Hui, Bian, Anning, Xing, Changying, Tang, Shaowen, Zhang, Jing, Jiang, Yao, Chen, Huimin, Yin, Caixia, Zhang, Lina, Wang, Jing, Huang, Yaoyu, Zhou, Wenbin, Wan, Huiting, Zha, Xiaoming, Zeng, Ming, and Wang, Ningning
- Subjects
- *
RENAL osteodystrophy , *CHRONIC kidney failure , *CHRONICALLY ill , *PARATHYROIDECTOMY , *FIBROBLAST growth factors , *METABOLIC bone disorders - Abstract
Blood bone metabolic biomarkers are noninvasive indices for evaluating metabolic bone diseases. We investigated the relationships between blood bone metabolic biomarkers and anemia in chronic kidney disease (CKD) patients and analyzed the effects of parathyroidectomy (PTX) on the above indices. In this cross-sectional study, 100 healthy controls and 239 CKD patients, including 46 secondary hyperparathyroidism (SHPT) patients with PTX, were enrolled. Moreover, a prospective study was conducted in which 28 PTX patients were followed up. The degree of anemia was classified as mild, moderate, or severe based on the tertiles of hemoglobin (Hb) levels of the anemic CKD patients, with cutoff values of 83 g/L and 102 g/L. Bone metabolic biomarkers, including calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), fibroblast growth factor 23 (FGF23), and α-klotho, were tested. The mean estimated glomerular filtration rate (eGFR) in CKD patients was 25.7 ± 36.0 ml/min/1.73 m2, and 84.10% of CKD patients had anemia. The baseline Hb levels in the mild, moderate, and severe anemia subgroups were 110.86 ± 5.99 g/L, 92.71 ± 5.96 g/L, and 67.38 ± 10.56 g/L, respectively. CKD patients had higher adjusted Ca, P, alkaline phosphatase (ALP), iPTH, and FGF23 levels and lower α-klotho levels than controls. Baseline adjusted Ca, P, iPTH, and α-klotho levels were associated with Hb levels in CKD patients. Blood adjusted Ca, P, and iPTH levels were correlated with anemia severity. After PTX (median interval: 6.88 months), anemia and high blood adjusted Ca, P, iPTH, and FGF23 levels were ameliorated, while α-klotho levels were increased. Blood adjusted Ca, P, iPTH, and α-klotho levels were correlated with Hb levels in CKD patients. Correction of bone metabolic disorders may be a therapeutic strategy for anemia treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Bone aluminum accumulation in the current era
- Author
-
Rodrigo Bueno de Oliveira, Aluízio Barbosa Carvalho, and Vanda Jorgetti
- Subjects
Chronic Kidney Disease-Mineral and Bone Disorder ,Aluminum ,Renal Insufficiency ,Chronic ,Treatment Outcome ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
In the last few years, evidence from the Brazilian Registry of Bone Biopsy (REBRABO) has pointed out a high incidence of aluminum (Al) accumulation in the bones of patients with CKD under dialysis. This surprising finding does not appear to be merely a passive metal accumulation, as prospective data from REBRABO suggest that the presence of Al in bone may be independently associated with major adverse cardiovascular events. This information contrasts with the perception of epidemiologic control of this condition around the world. In this opinion paper, we discussed why the diagnosis of Al accumulation in bone is not reported in other parts of the world. We also discuss a range of possibilities to understand why bone Al accumulation still occurs, not as a classical syndrome with systemic signs of intoxication, as occurred it has in the past.
- Published
- 2024
- Full Text
- View/download PDF
33. Analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory biomarkers in chronic kidney disease: impact of parathyroidectomy
- Author
-
Andre Kakinoki Teng, Eduardo Jorge Duque, Shirley Ferraz Crispilho, Wagner Domingues, Vanda Jorgetti, Luciene M. dos Reis, Rosilene M. Elias, and Rosa Maria Affonso Moysés
- Subjects
Renal Insufficiency ,Chronic ,Chronic Kidney Disease-Mineral and Bone Disorder ,Hyperparathyroidism, Secondary ,Parathyroidectomy ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Introduction: Secondary hyperparathyroidism (SHPT) is one of the causes for inflammation in CKD. We assessed the impact of parathyroidectomy (PTX) on neutrophil-to-lymphocyte (N/L) and platelet-to-lymphocyte (P/L) ratios in SHPT patients. Methods: A total of 118 patients [hemodialysis (HD, n = 81), and transplant recipients (TX, n = 37)] undergoing PTX between 2015 and 2021 were analyzed. Results: There was a significant reduction in calcium and PTH levels in both groups, in addition to an increase in vitamin D. In the HD group, PTX did not alter N/L and P/L ratios. In the TX group, there was a reduction in N/L and P/L ratios followed by a significant increase in total lymphocyte count. Conclusion: N/L and P/L ratios are not reliable biomarkers of inflammation in SHPT patients undergoing PTX. Uremia, which induces a state of chronic inflammation in dialysis patients, and the use of immunosuppression in kidney transplant recipients are some of the confounding factors that prevent the use of this tool in clinical practice.
- Published
- 2024
- Full Text
- View/download PDF
34. SOP's for CKD-MBD-Biomarkers
- Published
- 2022
35. Myocardial Remodeling in Early Chronic Kidney Disease—Mineral and Bone Disorder Model with Low Bone Turnover
- Author
-
Evdokia Bogdanova, Airat Sadykov, Galina Ivanova, Irina Zubina, Olga Beresneva, Olga Galkina, Marina Parastaeva, Vladimir Sharoyko, and Vladimir Dobronravov
- Subjects
chronic kidney disease—mineral and bone disorder ,myocardial remodeling ,phosphate ,calcineurin ,ERK1/2 ,PiT-2 ,Internal medicine ,RC31-1245 - Abstract
Chronic kidney disease—mineral and bone disorder (CKD-MBD) plays a significant role in causing cardiovascular morbidity and mortality related to CKD. CKD-MBD has been studied during advanced stages when changes in inorganic phosphate (Pi) and its hormonal regulation are obvious. The initial phases of myocardial remodeling (MR) in early CKD-MBD remain poorly understood. We induced mild CKD-MBD in spontaneously hypertensive rats using 3/4 nephrectomy. Animals were fed standard chow, containing 0.6% phosphate. In each animal, we analyzed indices of chronic kidney injury, bone turnover and Pi exchange, and assessed the myocardial histology and gene expression profile. Applied CKD-MBD models corresponded to human CKD S1-2 with low bone turnover and without an increase in systemic Pi-regulating factors (parathyroid hormone and fibroblast growth factor 23). In mild CKD-MBD models, we found MR features characterized by cardiomyocyte hypertrophy, interstitial and perivascular fibrosis, intramyocardial artery media thickening, along with alterations in Ppp3ca, Mapk1, Jag1, Hes1, Ptch1, Numb, Lgr4 and Bmp4 genes. Among other genes, the down-regulation of Jag1 was most tightly associated with either myocardial hypertrophy or fibrosis. Myocardial alterations concurrently occurred with mild CKD-MBD and comprised fibrosis preceding cardiomyocyte hypertrophy. The histological features of MR were associated with myocardial P accumulation in settings of low bone turnover, prior to a response of systemic Pi-regulating factors and with alterations in calcineurin, ERK1/2, Notch, BMP and Hedgehog genes.
- Published
- 2023
- Full Text
- View/download PDF
36. Association between serum phosphate levels and anemia in non-dialysis patients with chronic kidney disease: a retrospective cross-sectional study from the Fuji City CKD Network
- Author
-
Kazuhiko Kato, Akio Nakashima, Ichiro Ohkido, Kenji Kasai, and Takashi Yokoo
- Subjects
Anemia ,Chronic kidney disease ,Chronic kidney disease-mineral and bone disorder ,Erythropoietin stimulating agent ,Iron therapy ,Serum phosphate ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Patients with chronic kidney disease (CKD) present high mortality and morbidity rates despite the availability of various therapies. Although CKD-mineral and bone disorder (MBD) and renal anemia are important factors in patients with CKD, only few studies have analyzed the relationship between them. Therefore, this study aimed to evaluate the relationship between CKD-MBD and anemia in patients with CKD who did not receive erythropoiesis-stimulating agent or iron therapies. Methods This retrospective cross-sectional study included patients with CKD aged ≥ 20 years with estimated glomerular filtration rate (eGFR) categories G2a to G5 who were referred to the Fuji City General Hospital between April 2018 and July 2019. The exclusion criterion was ongoing treatment for CKD-MBD and/or anemia. Results The data of 300 patients with CKD were analyzed in this study. The median age of patients was 71 (range, 56.5–79) years. The median eGFR was 34 (range, 20–48) mL/min/1.73 m2, and the mean hemoglobin (Hb) level was 12.7 g/dL (standard deviation, 2.3), which decreased as the CKD stage increased. In a multivariate linear regression analysis of anemia-related factors, including age, renal function (eGFR), nutritional status, inflammation, and iron dynamics (serum iron level, total iron-binding capacity, ferritin levels), the serum phosphate levels were significantly associated with the Hb levels (coefficient [95% confidence interval], -0.73 [-1.1, -0.35]; P
- Published
- 2023
- Full Text
- View/download PDF
37. Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism
- Author
-
Soohoo, Melissa, Obi, Yoshitsugu, Rivara, Matthew B, Adams, Scott V, Lau, Wei Ling, Rhee, Connie M, Kovesdy, Csaba P, Kalantar-Zadeh, Kamyar, Arah, Onyebuchi A, Mehrotra, Rajnish, and Streja, Elani
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Kidney Disease ,Renal and urogenital ,Calcium ,Chronic Kidney Disease-Mineral and Bone Disorder ,Cohort Studies ,Humans ,Minerals ,Parathyroid Hormone ,Renal Dialysis ,Maintenance dialysis ,Mineral and bone disorders ,Marginal structural model ,In-center hemodialysis ,Peritoneal dialysis ,Extended-hours hemodialysis ,Nocturnal hemodialysis ,Urology & Nephrology ,Clinical sciences - Abstract
IntroductionChronic kidney disease-mineral and bone disorders (CKD-MBD) are prevalent in patients undergoing maintenance dialysis. Yet, there are limited and mixed evidence on the effects of different dialysis modalities involving longer treatment times or higher frequencies on CKD-MBD markers.MethodsThis cohort study used data from 132,523 incident dialysis patients treated with any of the following modalities: conventional thrice-weekly in-center hemodialysis, nocturnal in-center hemodialysis (NICHD), home hemodialysis (HHD), or peritoneal dialysis (PD) from 2007 to 2011. We used marginal structural models fitted with inverse probability weights to adjust for fixed and time-varying confounding and informative censoring. We estimated the average effects of treatments with different dialysis modalities on time-varying serum concentrations of CKD-MBD markers: albumin-corrected calcium, phosphate, parathyroid hormone (PTH), and alkaline phosphatase (ALP) using pooled linear regression.ResultsMost of the cohort were exclusively treated with conventional in-center hemodialysis, while few were ever treated with NICHD or HHD. At the baseline, PD patients had the lowest mean and median values of PTH, while NICHD patients had the highest median values. During follow-up, compared to hemodialysis patients, patients treated with NICHD had lower mean serum PTH (19.8 pg/mL [95% confidence interval: 2.8, 36.8] lower), whereas PD and HHD patients had higher mean PTH (39.7 pg/mL [31.6, 47.8] and 51.2 pg/mL [33.0, 69.3] higher, respectively). Compared to hemodialysis patients, phosphate levels were lower for patients treated with NICHD (0.44 mg/dL [0.37, 0.52] lower), PD (0.15 mg/dL [0.12, 0.19] lower), or HHD (0.33 mg/dL [0.27, 0.40] lower). There were no clinically meaningful associations between dialysis modalities and concentrations of calcium or ALP.ConclusionIn incident dialysis patients, compared to treatment with conventional in-center hemodialysis, treatments with other dialysis modalities with longer treatment times or higher frequency were associated with different patterns of serum phosphate and PTH. Given the recent growth in the use of dialysis modalities other than hemodialysis, the associations between the treatment and the CKD-MBD markers warrant additional study.
- Published
- 2022
38. Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients
- Author
-
Zaib Un Nisa Khan, PRINCIPAL INVESTIGATOR
- Published
- 2022
39. Integrated Diagnosis and Treatment of CKD on Outcomes
- Author
-
Dongliang Zhang, MD, Director of Nephrology Department of Beijing Jishuitan Hospital
- Published
- 2022
40. Marked vascular calcification in a patient on hemodialysis
- Author
-
Oe, Kazuho, Koyashiki, Yohei, and Takeda, Shin-ichi
- Published
- 2024
- Full Text
- View/download PDF
41. Calcium Balance Studies in Children With CKD and on Dialysis (Cal-Bal)
- Author
-
University of Kiel, Athens General Children's Hospital 'Pan. & Aglaia Kyriakou', and Cukurova University
- Published
- 2022
42. Relationships between blood bone metabolic biomarkers and anemia in patients with chronic kidney disease
- Author
-
Fan Li, Xiaoxue Ye, Guang Yang, Hui Huang, Anning Bian, Changying Xing, Shaowen Tang, Jing Zhang, Yao Jiang, Huimin Chen, Caixia Yin, Lina Zhang, Jing Wang, Yaoyu Huang, Wenbin Zhou, Huiting Wan, Xiaoming Zha, Ming Zeng, and Ningning Wang
- Subjects
Anemia ,chronic kidney disease–mineral and bone disorder ,bone metabolic biomarkers ,parathyroidectomy ,secondary hyperparathyroidism ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
AbstractIntroduction Blood bone metabolic biomarkers are noninvasive indices for evaluating metabolic bone diseases. We investigated the relationships between blood bone metabolic biomarkers and anemia in chronic kidney disease (CKD) patients and analyzed the effects of parathyroidectomy (PTX) on the above indices.Methods In this cross-sectional study, 100 healthy controls and 239 CKD patients, including 46 secondary hyperparathyroidism (SHPT) patients with PTX, were enrolled. Moreover, a prospective study was conducted in which 28 PTX patients were followed up. The degree of anemia was classified as mild, moderate, or severe based on the tertiles of hemoglobin (Hb) levels of the anemic CKD patients, with cutoff values of 83 g/L and 102 g/L. Bone metabolic biomarkers, including calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), fibroblast growth factor 23 (FGF23), and α-klotho, were tested.Results The mean estimated glomerular filtration rate (eGFR) in CKD patients was 25.7 ± 36.0 ml/min/1.73 m2, and 84.10% of CKD patients had anemia. The baseline Hb levels in the mild, moderate, and severe anemia subgroups were 110.86 ± 5.99 g/L, 92.71 ± 5.96 g/L, and 67.38 ± 10.56 g/L, respectively. CKD patients had higher adjusted Ca, P, alkaline phosphatase (ALP), iPTH, and FGF23 levels and lower α-klotho levels than controls. Baseline adjusted Ca, P, iPTH, and α-klotho levels were associated with Hb levels in CKD patients. Blood adjusted Ca, P, and iPTH levels were correlated with anemia severity. After PTX (median interval: 6.88 months), anemia and high blood adjusted Ca, P, iPTH, and FGF23 levels were ameliorated, while α-klotho levels were increased.Conclusions Blood adjusted Ca, P, iPTH, and α-klotho levels were correlated with Hb levels in CKD patients. Correction of bone metabolic disorders may be a therapeutic strategy for anemia treatment.
- Published
- 2023
- Full Text
- View/download PDF
43. Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease–Mineral and Bone Disorder in Non-Dialysis Adult Patients.
- Author
-
Fusaro, Maria, Pereira, Luciano, and Bover, Jordi
- Subjects
- *
RENAL osteodystrophy , *BONE fractures , *DIAGNOSIS , *KIDNEY diseases , *CARDIOVASCULAR diseases - Abstract
Chronic kidney disease (CKD) is a significant public health concern associated with significant morbidity and has become one of the foremost global causes of death in recent years. A frequent comorbidity of CKD is secondary hyperparathyroidism (SHPT), exemplified by high serum parathyroid hormone (PTH) levels. The mineral metabolism disturbances resulting from CKD and progression to SHPT are currently considered part of the definition of chronic kidney disease–mineral and bone disorder (CKD-MBD). However, CKD-MBD does not only include abnormalities in laboratory-measured parameters; it is a complex condition characterized by dysregulation of bone turnover, mineralization, growth and strength, accompanied by vascular or another soft-tissue calcification. Together, this increases the risk of bone fractures, cardiovascular disease, and overall mortality in CKD-MBD patients. Monitoring serum markers is essential in diagnosing SHPT and CKD-MBD, and there are several recognized indicators for prognosis, optimal clinical management and treatment response in late-stage kidney disease patients receiving dialysis. However, far fewer markers have been established for patients with non-dialysis CKD. This review provides an overview of current and emerging markers and tools used in the diagnosis and management of CKD-MBD in non-dialysis adult patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Association between serum phosphate levels and anemia in non-dialysis patients with chronic kidney disease: a retrospective cross-sectional study from the Fuji City CKD Network.
- Author
-
Kato, Kazuhiko, Nakashima, Akio, Ohkido, Ichiro, Kasai, Kenji, and Yokoo, Takashi
- Subjects
CHRONIC kidney failure ,RENAL osteodystrophy ,CHRONICALLY ill ,IRON in the body - Abstract
Background: Patients with chronic kidney disease (CKD) present high mortality and morbidity rates despite the availability of various therapies. Although CKD-mineral and bone disorder (MBD) and renal anemia are important factors in patients with CKD, only few studies have analyzed the relationship between them. Therefore, this study aimed to evaluate the relationship between CKD-MBD and anemia in patients with CKD who did not receive erythropoiesis-stimulating agent or iron therapies. Methods: This retrospective cross-sectional study included patients with CKD aged ≥ 20 years with estimated glomerular filtration rate (eGFR) categories G2a to G5 who were referred to the Fuji City General Hospital between April 2018 and July 2019. The exclusion criterion was ongoing treatment for CKD-MBD and/or anemia. Results: The data of 300 patients with CKD were analyzed in this study. The median age of patients was 71 (range, 56.5–79) years. The median eGFR was 34 (range, 20–48) mL/min/1.73 m
2 , and the mean hemoglobin (Hb) level was 12.7 g/dL (standard deviation, 2.3), which decreased as the CKD stage increased. In a multivariate linear regression analysis of anemia-related factors, including age, renal function (eGFR), nutritional status, inflammation, and iron dynamics (serum iron level, total iron-binding capacity, ferritin levels), the serum phosphate levels were significantly associated with the Hb levels (coefficient [95% confidence interval], -0.73 [-1.1, -0.35]; P < 0.001). Subgroup analysis revealed a robust association between serum phosphate levels and Hb levels in the low-ferritin (coefficient [95% confidence interval], -0.94 [-1.53, -0.35]; P = 0.002) and advanced CKD groups (coefficient [95% confidence interval], -0.89 [-1.37, -0.41]; P < 0.001). Conclusions: We found an association between high serum phosphate levels and low Hb levels in patients with CKD not receiving treatment for anemia. These results underscore the possibility of a mechanistic overlap between CKD-MBD and anemia. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
45. Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD)
- Author
-
nooshin dalili, Principal Investigator
- Published
- 2022
46. Corrigendum: Fucoidan ameliorates renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD-MBD model rats by targeting FGF23-Klotho signaling axis.
- Subjects
RENAL osteodystrophy ,METABOLIC bone disorders ,LABORATORY rats ,CHINESE medicine ,MEDICAL schools - Abstract
This document is a corrigendum published in the journal Frontiers in Pharmacology. It corrects an error in Figure 5 of the article titled "Fucoidan ameliorates renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in the CKD-MBD model rats by targeting FGF23-Klotho signaling axis." The authors apologize for the error and state that it does not affect the scientific conclusions of the article. The corrected figure and its caption are provided in the corrigendum. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
47. Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
- Author
-
Anhui Provincial Hospital, Huadong Hospital, Longhua Hospital, and Bing Shu, Associate Professor
- Published
- 2021
48. Renal osteodystrophy and clinical outcomes: a prospective cohort study
- Author
-
Cinthia Esbrile Moraes Carbonara, Joaquim Barreto, Noemi Angelica Vieira Roza, KélciaRosana da Silva Quadros, Luciene Machado dos Reis, Aluízio Barbosa de Carvalho, Andrei C. Sposito, Vanda Jorgetti, and Rodrigo Bueno de Oliveira
- Subjects
Chronic Kidney Disease-Mineral and Bone Disorder ,Renal Osteodystrophy ,Renal Insufficiency, Chronic ,Clinical Outcomes ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Introduction: Renal osteodystrophy (ROD) refers to a group of bone morphological patterns that derive from distinct pathophysiological mechanisms. Whether the ROD subtypes influence long-term outcomes is unknown. Our objective was to explore the relationship between ROD and clinical outcomes. Methods: This study is a subanalysis of the Brazilian Registry of Bone Biopsies (REBRABO). Samples from individual patients were classified as having osteitis fibrosa (OF), mixed uremic osteodystrophy (MUO), adynamic bone disease (ABD), osteomalacia (OM), normal/minor alterations, and according to turnover/mineralization/volume (TMV) system. Patients were followed for 3.4 yrs. Clinical outcomes were: bone fractures, hospitalization, major adverse cardiovascular events (MACE), and death. Results: We enrolled 275 participants, of which 248 (90%) were on dialysis. At follow-up, 28 bone fractures, 97 hospitalizations, 44 MACE, and 70 deaths were recorded. ROD subtypes were not related to outcomes. Conclusion: The incidence of clinical outcomes did not differ between the types of ROD.
- Published
- 2023
- Full Text
- View/download PDF
49. The effect of a training program on the self‐care efficacy of hemodialysis patients with mineral and bone disorders: A quasi‐experimental study.
- Author
-
Tashakor, Sedigheh, Bagherian, Behnaz, Salmanpour, Zahra, and Mehdipour‐Rabori, Roghayeh
- Abstract
Background and Aims: Patients who have chronic kidney disease (CKD) and mineral and bone disorders (MBD) often do not know much about their diseases. A training program can help them improve their quality of life. This study aimed to assess the effect of a training program on the self‐care efficacy of the hemodialysis patients with MBDs in southeastern Iran. Method: We conducted a quasi‐experimental study involving 49 patients with CKD‐MBD in southeastern Iran in 2021. The patients were randomly assigned to either the control or intervention group. The intervention group received 12 self‐care training sessions delivered through WhatsApp, whereas the control group received routine information. We administered CKD‐MBD knowledge and behavior questionnaires of the intervention, and measured laboratory parameters before and 1 month after the intervention. The data were analyzed by SPSS15 with descriptive and analytical statistics. Paired t test, independent t, analysis of covariance, and Mann–Whitney U tests were using for data analysis. Results: The mean knowledge scores of the control group were 4.78 ± 1.78 and 6.22 ± 2.11 before and after the intervention, respectively (p = 0.200), whereas the mean knowledge scores of the intervention group were 6.08 ± 2.24 and 22.23 ± 4.55 before and after the intervention, respectively (p = 0.001). The mean behavior scores of the control and intervention groups were 75.61 ± 7.13 and 73.85 ± 7.49 before the intervention, respectively (p = 0.070), but they received the mean scores of 78.87 ± 5.58 and 82.50 ± 5.35 after the intervention, respectively (p = 0.001). The result showed a significant increase in the mean knowledge and behavior scores after the intervention. The researchers found no significant difference in the mean scores of the laboratory parameters between them before and after the intervention (p = 0.090); therefore, the intervention could not affect the laboratory parameters. Conclusion: To sum up, the study found that the training program improved the knowledge and behavior of hemodialysis patients with MBD. WhatsApp was a good and cheap way to teach them self‐care, and it helped them do it better. These results implied that this training program could help the patients have a better quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects.
- Author
-
Komaba, Hirotaka
- Subjects
- *
RENAL osteodystrophy , *FIBROBLAST growth factors , *KIDNEY failure , *BROWN adipose tissue - Abstract
Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) each play a central role in the pathogenesis of chronic kidney disease-mineral and bone disorder (CKD-MBD). Both hormones increase as kidney function declines, presumably as a response to maintain normal phosphate balance, but when patients reach kidney failure, PTH and FGF23 fail to exert their phosphaturic effects, leading to hyperphosphatemia and further elevations in PTH and FGF23. In patients with kidney failure, the major target organ for PTH is the bone, but elevated PTH is also associated with mortality presumably through skeletal and nonskeletal mechanisms. Indeed, accumulated evidence suggests improved survival with PTH-lowering therapies, and a more recent study comparing parathyroidectomy and calcimimetic treatment further suggests a notion of "the lower, the better" for PTH control. Emerging data suggest that the link between SHPT and mortality could in part be explained by the action of PTH to induce adipose tissue browning and wasting. In the absence of a functioning kidney, the classical target organ for FGF23 is the parathyroid gland, but FGF23 loses its hormonal effect to suppress PTH secretion owing to the depressed expression of parathyroid Klotho. In this setting, experimental data suggest that FGF23 exerts adverse nontarget effects, but it remains to be confirmed whether FGF23 directly contributes to multiple organ injury in patients with kidney failure and whether targeting FGF23 can improve patient outcomes. Further efforts should be made to determine whether intensive control of SHPT improves clinical outcomes and whether nephrologists should aim at controlling FGF23 levels just as with PTH levels. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.